CARDIOVASCULAR
hamburger

COMPREHENSIVE SOLUTIONS FOR HEART FAILURE MANAGEMENT

BREAKTHROUGH TECHNOLOGIES WITH PROVEN CLINICAL OUTCOMES

An estimated 5.7 million American adults are affected by heart failure (HF).1 Every year in the United States, approximately 1 million patients are hospitalized with a primary discharge diagnosis of HF, with HF the leading cause of hospitalizations for adults aged 65 or older.2 The cost of treating HF in the U.S. is expected to reach $70 billion by 2030.3 In 2012, Medicare’s average cost per beneficiary with a diagnosis of heart failure exceeded $33,000 per year, approximately three times the cost of an average beneficiary.4


While the Centers for Medicare and Medicaid Services (CMS) has developed ongoing and planned reimbursement reform programs, we have dedicated our efforts to providing you with the broadest scope of technologically innovative, clinically proven and outcome-driven solutions for better heart failure management. The benefits of frequent insight and early intervention that our technologies can give you are matched only by our ability to increase efficacy while decreasing the economic cost associated with cardiovascular care.

LATEST TECHNOLOGY AND INNOVATION
CARDIOMEMS™ HF SYSTEM: OVERVIEW

Watch an introduction to the CardioMEMS™ HF System, pulmonary artery (PA) pressure monitoring.

HEARTMATE 3™ LVAD WITH FULL MAGLEV™ FLOW TECHNOLOGY

Watch a brief overview of the HeartMate 3™ LVAD with Full MagLev™ Flow Technology.

HEARTMATE II™ LVAS: FEATURES AND COMPONENTS

Watch a brief overview of the features and parts of the HeartMate II™ LVAS.

[Ljava.lang.String;@53adb353
IMPROVING OUTCOMES WITH THE CARDIOMEMS™ HF SYSTEM

Directly monitoring PA pressure with the CardioMEMS™ HF System not only notifies you if a patient’s heart failure is worsening, but also allows you to intervene earlier, adjusting medication or making other treatment changes

In a retrospective sub-analysis of the CHAMPION trial, the 22% of study patients with preserved ejection fraction had a 50% reduction in heart failure hospitalizations - an even greater reduction than that among study patients as a whole.8,9,10

See more CardioMEMS™ HF System evidence.

Quadra Assure Allure MP
PROVIDING ADDITIONAL CRT OPTIONS WITH MULTIPOINT™ PACING

MultiPoint™ Pacing technology, a feature of the Quadra Assura MP™ cardiac resynchronization therapy defibrillator (CRT-D) and the Quadra Allure MP™ cardiac resynchronization pacemaker (CRT-P), which pair with the Quartet™ Quadripolar LV lead , lets you pace from two left ventricular (LV) sites. Pacing from two LV sites is designed to capture more tissue and provide additional CRT options to change:

·         Pattern of depolarization

·         Engagement of areas around scar tissue

·         Hemodynamics

·         Resynchronization

Post-hoc subanalysis of the recent MPP™ technology U.S. IDE study yielded clinical evidence for improved outcomes with MPP™ technology. See the MPP™ technology U.S. IDE evidence  along with clinical evidence for our other heart failure solutions.

 

REFERENCES

*At the 6-month primary endpoint in the MOMENTUM 3 trial. (MOMENTUM 3 = Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 LVAD.)
**As defined by zero incidence of pump thrombosis in the MOMENTUM 3 trial at 6 months.
1. Mozaffarian, D., Benjamin, E. J., Go, A., A., Arnett, D. K., Blaha, M. J., Cushman, M., ... Truner, M. B. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, (2015). Heart disease and stroke statistics—2016 update: A report from the American Heart Association. Circulation, 132, e1-e323. http://dx.doi.org/10.1161/CIR.0000000000000350

2. Akintoye, E., Briasoulis, A., Egbe, A., Dunlay, S. M., Kushwaha, S., Levine, D., Afonso, L., Mozaffarian, D., Weinberger, J., (2017). National trends in admission and in-hospital mortality of patients with heart failure in the United States (2001-2014). Journal of the American Heart Association. 6. http://dx.doi.org/10.1161/JAHA.117.006955

3. American Heart Association. (2013, April 24). Costs to treat heart failure expected to more than double by 2030. Retrieved from http://newsroom.heart.org/news/costs-to-treat-heart-failure-expected-to-more-than-double-by-2030

4. Centers for Medicare & Medicaid Services. Chronic Conditions Among Medicare Beneficiaries Chartbook: 2012 Edition. Retrieved from http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/Downloads/2012Chartbook.pdf Accessed April 23, 2014.

5. Abraham, W. T., Stevenson, L., Bourge, R. C., Lindenfeld, J., Bauman, J., Adamson, P. B. (2016). Sustained efficacy of pulmonary artery pressure to guide to adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomized trial. The Lancet, 387(10017), 453-461. http://dx.doi.org/10.1016/S0140-6736(15)007233-0

6. Mehra, M. R., Yoshifumi, N., Uriel, N., Goldstein, D. J., Cleveland, J. C. Jr., Colombo, Paolo C., … Salerno, C. for the MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. (2016, November 16). The New England Journal of Medicine, 376,440-50. http://dx.doi.org/10.1056/NEJMoa1610426

7. Abraham, W. T., Adamson, P. B., Stevenson, L. W., Costanzo, M. R., Bourge, R. C., Bauman, J., … Yadav, J. (2015, May). Pulmonary artery pressure management in heart failure patients with cardiac resynchronization therapy or implantable cardioverter defibrillator devices significantly reduces heart failure hospitalizations and mortality above and beyond background guide-directed medical therapy. Presented at the meeting of the Heart Rhythm Society, Boston, MA.

8. Abraham, W. T., Stevenson, L. W., Bourge, R. C., Lindenfeld, J. A., Bauman, J. G., Adamson, P. B., for the CHAMPION Trial Study Group. (2016). Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. The Lancet, 387 (10017), 453-461. http://dx.doi.org/10.1016/S0140-6736(15)00723-0

9. Adamson, P. B., Abraham, W. T., Bourge, R. C., Costanzo, M. R., Hasan, A., Yadav, C., et al. (2014). Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circulation: Heart Failure, 7 (6), 935-944. http://dx.doi.org/10.1161/circheartfailure.113.001229

10. Sharma, K., Kass, D. A. (2014). Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circulation Research, 115 (1), 79-96. http://dx.doi.org/10.1161/circresaha.115.302922

CUSTOMER
SERVICE

Our customer service experts can help with your
product orders or questions.

A natural monument

OUR PRODUCTS

See our featured innovations and technologies, full product catalog and approach to disease state management.

SJM-CV WEB-0718-0014

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?